KUBTEC is hiring, purchases property for future expansion

Through our 15-year history, we have become known for our proprietary award-winning products that are challenging the status quo of breast cancer surgery. This is creating huge demands for our solutions. Our 3D MOZART tomosynthesis technology has been shown to empower surgeons in the operating theater by reducing avoidable rehospitalizations by 50%(1).

With our growing clinical success comes commercial success. In 2018 we purchased our new state-of-the-art facility, which includes an auditorium for training and a fully-featured demo studio. Our CEO Vikram Butani announced on Thursday that with our plans to grow even further, he secured an adjacent parcel of land to our facility for our future expansion.

“We’re looking for talented and passionate individuals to join our growing team. We want great people working for us and creative people who think outside of the box to get things done. We have several roles open from Engineering to Sales and more,” Butani said.

If you are interested in joining a growing organization and looking for your next opportunity, we would love to hear from you. Email us at careers@kubtec.com, and tell us why you would be a great addition to our growing team.

About KUBTEC
KUBTEC is challenging the status quo of breast cancer surgery and the excessive volume of re-excision surgeries. Through continuous research and development of our proprietary 3D tomosynthesis technology, KUBTEC is empowering surgeons with immediate visualization of surgical margins in the operating theater, helping to reduce re-excision rates, preserve healthy breast tissue, and ultimately improve patient outcomes. For more information, visit https://kubtec.com.

1. Differences in Re-excision Rates for Breast Conserving Surgery Using Intraoperative 2D vs. 3D Tomosynthesis Specimen Radiograph. Andrea Colton MD, Carissia Calvo MD, Ali Mokdad MD, Katherine Pouns, B.A, Edward Clifford MD, Deborah Farr MD, James Huth MD, Rachel Wooldridge MD, Marilyn Leitch MD, and Natalia Partain MD. Department of Surgery, Division of Surgical Oncology; University of Texas Southwestern, Dallas, Texas